The use of bronchodilators and glucocorticoids did not prove to have any benefits with respect to rates of hospitalization and readmission, duration of the disease and overall disease outcome.

What is known about acute bronchiolitis:

How to talk with patients and parents about acute bronchiolitis:

Inform parents that it is a common disease and usually self-limiting respiratory infection in children. RSV goes away on its own, but it may take a week or two to get completely well.

You can give the following advice:

This EAP recommendation is in accordance with Choosing Wisely recommendations of:

American Academy of Family Physicians (AFP): 
https://www.aafp.org/pubs/afp/collections/choosing-wisely/70.html

References:

  • Cahill AA, Cohen J. Improving Evidence Based Bronchiolitis Care. Clin Pediatr Emerg Med. 2018 Mar;19(1):33-39. PMID: 32288646

  • Cai Z, Lin Y, Liang J. Efficacy of salbutamol in the treatment of infants with bronchiolitis: A meta-analysis of 13 studies. Medicine (Baltimore). 2020 Jan;99(4):e18657. PMID: 31977855

  • Dalziel SR, Haskell L, O’Brien S, Borland ML, Plint AC, Babl FE, Oakley E. Bronchiolitis. Lancet. 2022 Jul 30;400(10349):392-406. PMID: 35785792

  • Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al. Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis. Pediatrics. 2014 Nov 1;134(5): e1474–502. PMID: 26430140

  • Zhang XL et al. Expert consensus on the diagnosis, treatment, and prevention of respiratory syncytial virus infections in children. World J Pediatr. 2024 Jan;20(1):11-25. PMID: 38064012
""
 

Core-MD Project

Coordinating Research and Evidence for Medical Devices (CORE-MD)

New ways to test high-risk medical devices.

 

Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.


It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.

EAP Representative:

Your Enquiries Are Welcome

We will respond to you by Email